Key result
Cochrane protocol outlines planned review comparing GLP-1 receptor agonists with metformin for CV prevention.
Why the study?
Do glucagon-like peptide-1 receptor agonist-based regimens prevent cardiovascular events compared to metformin-based regimens in adults with type 2 diabetes mellitus?
Systematic Review
Do glucagon-like peptide-1 receptor agonist-based regimens prevent cardiovascular events compared to metformin-based regimens in adults with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
This is a protocol for a Cochrane review to evaluate the clinical benefits and adverse effects of GLP-1 receptor agonists versus metformin for cardiovascular prevention in type 2 diabetes.
OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: To assess the clinical benefits and adverse effects of glucagon-like peptide-1 receptor agonist-based regimens, compared with metformin-based glucose-lowering regimens, for preventing cardiovascular events including all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and metabolic adverse events (including transient hypoglycemia) in adults with type 2 diabetes mellitus across primary and secondary prevention settings.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a systematic review in type 2 diabetes mellitus. Glucagon-like peptide-1 receptor agonist-based regimens vs. Metformin-based glucose-lowering regimens was evaluated on Cardiovascular events including all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and metabolic adverse events. This is a protocol for a Cochrane review to assess GLP-1 receptor agonists compared with metformin for preventing cardiovascular disease in adults with type 2 diabetes mellitus; no results are available.
Synapse has enriched 10 related papers. Consider them for comparative context: